RESUMEN
AIM: In pyridoxine dependent epilepsy (PDE), patients usually present with neonatal seizures. A small subgroup is characterized by late-onset beyond 2 months of age. We aim to analyze the observation of relatively good cognitive outcome in this subgroup of late-onset PDE patients. METHODS: We retrospectively analyzed data from four metabolically and genetically confirmed late-onset patients with PDE due to antiquitin (ALDH7A1) deficiency. Data were analyzed regarding ALDH7A1 mutations, alpha-Aminoadipic semialdehyde (α-AASA) and pipecolic acid (PA) levels, medication during pregnancy, delivery, treatment delay, amount of seizures, pyridoxine dose, adjuvant therapy and findings on brain MRI. RESULTS: Results showed that three patients had relatively good outcome (IQ 80-97), while one patient did not undergo formal testing and was considered mildly delayed. We were unable to find a clear association between the above-mentioned variables and cognitive outcome, although a less severe genotype may be present in three patients, and maternal medication could be accountable for better outcome in two patients. INTERPRETATION: We suggest that favorable outcome in late onset PDE might be explained by a combination of factors. A yet unknown protective factor, different genetic variations, functional variation and secondarily variation in treatment regimens and absence of neonatal seizure induced brain damage.
Asunto(s)
Edad de Inicio , Epilepsia/complicaciones , Discapacidad Intelectual/genética , Aldehído Deshidrogenasa/genética , Epilepsia/genética , Femenino , Genotipo , Humanos , Lactante , Discapacidad Intelectual/epidemiología , Inteligencia/genética , Imagen por Resonancia Magnética , Masculino , Mutación , Piridoxina/uso terapéutico , Estudios RetrospectivosRESUMEN
INTRODUCTION: Acquired demyelinating syndromes (ADS) are immune-mediated demyelinating disorders of the central nervous system in children. A nationwide, multicentre and prospective cohort study was initiated in the Netherlands in 2006, with a reported ADS incidence of 0.66/100,000 per year and MS incidence of 0.15/100,000 per year in the period between 2007 and 2010. In this study, we provide an update on the incidence and the long-term follow-up of ADS in the Netherlands. METHODS: Children < 18 years with a first attack of demyelination were included consecutively from January 2006 to December 2016. Diagnoses were based on the International Paediatric MS study group consensus criteria. Outcome data were collected by neurological and neuropsychological assessments, and telephone call assessments. RESULTS: Between 2011 and 2016, 55/165 of the ADS patients were diagnosed with MS (33%). This resulted in an increased ADS and MS incidence of 0.80/100,000 per year and 0.26/100,000 per year, respectively. Since 2006 a total of 243 ADS patients have been included. During follow-up (median 55 months, IQR 28-84), 137 patients were diagnosed with monophasic disease (56%), 89 with MS (37%) and 17 with multiphasic disease other than MS (7%). At least one form of residual deficit including cognitive impairment was observed in 69% of all ADS patients, even in monophasic ADS. An Expanded Disability Status Scale score of ≥ 5.5 was reached in 3/89 MS patients (3%). CONCLUSION: The reported incidence of ADS in Dutch children has increased since 2010. Residual deficits are common in this group, even in monophasic patients. Therefore, long-term follow-up in ADS patients is warranted.
Asunto(s)
Enfermedades del Sistema Nervioso Central/epidemiología , Enfermedades Desmielinizantes/epidemiología , Adolescente , Enfermedades del Sistema Nervioso Central/terapia , Niño , Preescolar , Enfermedades Desmielinizantes/terapia , Femenino , Estudios de Seguimiento , Humanos , Incidencia , Masculino , Países Bajos/epidemiología , Estudios ProspectivosAsunto(s)
Epilepsia Refleja/diagnóstico , Epilepsia Refleja/etiología , Juego e Implementos de Juego , Convulsiones/diagnóstico , Convulsiones/etiología , Adolescente , Electroencefalografía/métodos , Epilepsia Generalizada/diagnóstico , Epilepsia Generalizada/etiología , Epilepsia Generalizada/fisiopatología , Epilepsia Refleja/fisiopatología , Humanos , Masculino , Convulsiones/fisiopatologíaRESUMEN
We report a case of a girl who presented with typical absence seizures at age of 4.5 years. EEG showed absence seizures of sudden onset with 3 Hz spike-and-waves that also correlated with the clinical absences. The seizure semiology included subtle deviation of the eyes which prompted MRI investigation of the brain. This showed a periventricular nodular heterotopia in the mid to anterior horn of the right lateral ventricle. Although possibly coincidental, periventricular heterotopia are considered to be epileptogenic and this association has been reported once before. Migration disorders, such as in the periventricular heterotopia of our patient, may influence the formation and excitability of the striato-thalamo-cortical network involved in the generation of 3 Hz spike-waves.
Asunto(s)
Epilepsia Tipo Ausencia/etiología , Epilepsia Tipo Ausencia/patología , Heterotopia Nodular Periventricular/complicaciones , Heterotopia Nodular Periventricular/patología , Anticonvulsivantes/uso terapéutico , Preescolar , Quimioterapia Combinada , Electroencefalografía , Epilepsia Tipo Ausencia/tratamiento farmacológico , Femenino , Humanos , Lamotrigina , Imagen por Resonancia Magnética , Triazinas/administración & dosificación , Ácido Valproico/administración & dosificaciónRESUMEN
BACKGROUND: Brain arteriovenous malformations (BAVMs) are thought to be sporadic developmental vascular lesions, but familial occurrence has been described. We compared the characteristics of patients with familial BAVMs with those of patients with sporadic BAVMs. METHODS: We systematically reviewed the literature on patients with familial BAVMs. Three families that were found in our centre were added. Age, sex distribution and clinical presentation of the identified patients were compared with those in population based series of patients with sporadic BAVMs. Furthermore, we calculated the difference in mean age at diagnosis of parents and children to study possible anticipation. RESULTS: We identified 53 patients in 25 families with BAVMs. Mean age at diagnosis of patients with familial BAVMs was 27 years (range 9 months to 58 years), which was younger than in the reference population (difference between means 8 years, 95% CI 3 to 13 years). Patients with familial BAVMs did not differ from the reference populations with respect to sex or mode of presentation. In families with BAVMs in successive generations, the age of the child at diagnosis was younger than the age of the parent (difference between means 22 years, 95% CI 13 to 30 years), which suggests clinical anticipation. CONCLUSIONS: Few patients with familial BAVMs have been described. These patients were diagnosed at a younger age than sporadic BAVMs whereas their mode of presentation was similar. Although there are indications of anticipation, it remains as yet unclear whether the described families represent accidental aggregation or indicate true familial occurrence of BAVMs.
Asunto(s)
Malformaciones Arteriovenosas Intracraneales/genética , Adolescente , Adulto , Anticipación Genética/genética , Niño , Preescolar , Femenino , Humanos , Lactante , Malformaciones Arteriovenosas Intracraneales/diagnóstico , Masculino , Persona de Mediana Edad , Telangiectasia Hemorrágica Hereditaria/diagnóstico , Telangiectasia Hemorrágica Hereditaria/genética , Factor de Crecimiento Transformador beta/genéticaRESUMEN
Growth retardation is one of the clinical characteristics of glycogen storage disease (GSD) type IX. Initial growth retardation has been described in a few case reports, followed by a complete catch-up in growth. This study aimed to determine the growth pattern of patients with GSD IX. Growth charts of 51 male Dutch patients with GSD IX (age 0-33 years, median follow-up time 8.3 years (range 0-30.5 years)) were studied retrospectively and compared with Dutch standard growth charts. Patients had a normal height at birth, significant growth retardation between the ages of 2 and 10 years (mean z-score -1.96), delayed growth spurt in puberty and catch-up towards quite normal final height (mean z-score -0.55). We conclude that GSD IX patients have a specific growth pattern characterized by initial growth retardation, a late growth spurt and complete catch-up in final height. Intervention for growth retardation is therefore in general not warranted. It is speculated that mild hypoglycaemia related to the disorder may cause endocrine changes. Because the glucose need per kg bodyweight decreases with age, the enzyme defect becomes less important with ageing and the effect on growth diminishes.
Asunto(s)
Enfermedades Genéticas Ligadas al Cromosoma X/genética , Enfermedad del Almacenamiento de Glucógeno/genética , Trastornos del Crecimiento/genética , Fosforilasa Quinasa/deficiencia , Fosforilasa Quinasa/genética , Adolescente , Adulto , Envejecimiento/fisiología , Estatura/genética , Niño , Preescolar , Estudios de Seguimiento , Enfermedades Genéticas Ligadas al Cromosoma X/patología , Enfermedad del Almacenamiento de Glucógeno/enzimología , Trastornos del Crecimiento/patología , Humanos , Lactante , Masculino , Estudios RetrospectivosRESUMEN
It is generally accepted that renal transplantation as a routine therapy for terminal stage renal patients has various medical advantages over chronic haemodialysis. A comparison of costs of both types of treatment clearly demonstrates a considerable difference also in favour of the former. This comparison is based on patient data from the Leyden University Hospital and on the tarrifs agreed upon by the Dutch Public Health Insurance Companies for haemodialysis treatment in 1973. (In this article only cost of center dialysis has been compared with cost of transplantation. In Holland, so far, no comparable data on the cost of home dialysis are available.) Renal transplantation, including 12 months of post-operative care, requires some Dfl. 45,000 (or + 18,000) whereas one year of chronic center haemodialysis cost Dfl. 65,000 (or + 26,000). The cost of treatment of a patient with a well-functioning graft in the second and following years normally does not exceed Dfl. 8,000 (or + 3,200) per year. These figures demonstrate the enormous economic advantage of transplantation as compared to chronic center haemodialysis, and that together with the medical advantages of transplantation should be sufficient reason to promote transplantation.